NCT03148418
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Immunotherapy, Therapeutic Antibody
Key Eligibility Criteria:
Gender: All
Age: Child, Adult, Older Adult
Location of Metastases:
Additional Notes: Patients must have been previously enrolled in a Genentech− and/or F. Hoffmann-La Roche Ltd-sponsored atezolizumab study
Exclusions:
https://ClinicalTrials.gov/show/NCT03148418